|
業務類別
|
Biotechnology |
|
業務概覽
|
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. |
| 公司地址
| 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087 |
| 電話號碼
| +1 888 378-6240 |
| 傳真號碼
| -- |
| 公司網頁
| https://mineralystx.com |
| 員工數量
| 76 |
| Mr. Eric Warren, R.Ph. |
Chief Commercial Officer |
-- |
12/03/2026 |
| Mr. Jon Congleton |
President, Chief Executive Officer and Director |
美元 636.50K |
08/04/2026 |
| Dr. David Rodman, M.D. |
Chief Medical Officer |
美元 533.00K |
12/03/2026 |
| Mr. Adam S. Levy |
Chief Financial Officer, Principal Accounting Officer and Secretary |
美元 532.00K |
12/03/2026 |
|
|
| Dr. Alexander M. Gold, M.D. |
Independent Director |
08/04/2026 |
| Ms. Daphne Karydas, M.B.A. |
Independent Director |
08/04/2026 |
| Mr. Glenn P. Sblendorio |
Chairman of the Board |
08/04/2026 |
| Dr. Srinivas Akkaraju, M.D.,PhD |
Independent Director |
08/04/2026 |
| Mr. Jon Congleton |
President, Chief Executive Officer and Director |
08/04/2026 |
| Dr. Derek DiRocco, PhD |
Independent Director |
08/04/2026 |
| Dr. Brian Taylor Slingsby, M.D.,PhD |
Independent Director |
08/04/2026 |
|
|
|
|
